Articles tagged with Antiinflammatory Drugs
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
This technology delivers IL-10 mRNA to lung tissue, reducing inflammation and injury in acute lung injury and ARDS, while minimizing side effects. The lung-targeting lipid nanoparticles sustain therapeutic protein expression directly within lung tissue, reducing systemic exposure and improving treatment effectiveness.
Researchers found that over-the-counter probiotics contain only 36 unique species of bacteria, with most common species being forms of Lactobacillus. The analysis suggests a lack of consistency in the combination of species used to support gut health and vaginal health claims.
A new anti-inflammatory molecule has shown promising results in protecting neurons and delaying disease progression in mice with Parkinson's disease. The study, published in Neuropharmacology, found that the Ac2-26 peptide mitigated neuroinflammation and protected against cell death.
A new review highlights advances in preventing bone loss in people with rheumatoid arthritis, showing that modern antirheumatic therapies can significantly reduce both localized erosions and generalized bone loss. Emerging imaging technologies like HR-pQCT have been found to detect subtle bone erosions earlier and more sensitively.
Researchers have found a widely available drug combination to be an effective treatment for patients with systemically active Sjögren's disease. The combination of leflunomide and hydroxychloroquine reduced disease activity while maintaining a favorable safety profile.
A University of Bristol-led pilot trial found that tocilizumab reduced symptoms of depression, fatigue and anxiety in people who had not responded to standard treatments. The study provides early evidence for a new treatment option for patients with inflammation-related depression.
Researchers at Ben-Gurion University of the Negev identified how semaglutide and colchicine protect the heart from Atrial Fibrillation by targeting different biological pathways. The study found that these medications can prevent the development of AF even in non-obese patients.
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
Researchers have developed a low-cost fake drug detector that uses an infrared sensor to track pill dissolution rates. The device can identify legitimate medications from counterfeit ones with high accuracy, making it a valuable tool in the fight against global health threats.
Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.
New research shows that Rytvela, an anti-inflammatory drug candidate, decreases premature birth and infant mortality when administered after the onset of preterm labor in a preclinical mouse model. The treatment prolongs gestation and fetal growth while allowing newborn organs to develop in utero.
A new study led by Dr. Chu Chen suggests that combining THC with celecoxib may improve cognition and reduce Alzheimer's-related brain pathology in mice. The combination produced better outcomes than low-dose THC alone, including improved learning and memory performance and reduced markers of neuroinflammation.
A research team at Goethe University Frankfurt has compiled a catalog of human E3 ligases and mapped their relationships, revealing family-specific functions. The study identifies 40 additional E3 ligases suitable for PROTAC development, expanding the range of tissues and diseases targeted by degradation therapies.
A randomized controlled trial found that lipoic acid had a small beneficial effect on slowing brain atrophy in people with progressive multiple sclerosis. However, it did not improve walking speed as the primary clinical outcome. The study suggests that lipoic acid may be worth further investigation for its potential benefits.
A study published in Biological Psychiatry identifies a distinct immuno-inflammatory biomarker in the brain linked to immune system dysfunction and poorer response to standard treatments. The findings provide potential value for clinical prediction and precision therapies.
Researchers from Brazil confirm the safety and efficacy of Alternanthera littoralis (Joseph's Coat) in reducing inflammation and modulating inflammatory mediators. The study's findings support the plant's medicinal potential and suggest a safety profile at therapeutic doses.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Headache disorders affect nearly one in every three people, causing significant disability and health loss. Migraine and medication overuse drive most of the global burden, emphasizing the need for improved prevention, management, and access to care.
A Cochrane review found that low-dose colchicine reduced heart attacks and strokes in people with a history of heart disease or stroke. The study involved nearly 23,000 participants and showed that taking colchicine could prevent about two of each heart attack and stroke among those with cardiovascular disease.
Researchers discovered reduced concentrations of key lipids in patients with NSAID-exacerbated respiratory disease (N-ERD), whereas healthy controls showed increased levels with low-dose aspirin. Elevated lipid mediators linked to inflammation were also observed, suggesting potential new diagnostic and treatment options.
Scientists at NYU Pain Research Center identified the EP2 receptor as the main cause of inflammatory pain but not inflammation. Blocking this receptor silenced pain responses without affecting inflammation, offering a new strategy for treating prostaglandin-mediated pain.
Conventional treatment methods used by municipal wastewater treatment facilities are ineffective at removing common pharmaceuticals like Prozac, fluoxetine, and loratadine from wastewater. These drugs are discharged into lakes, rivers, and streams, posing risks to aquatic organisms.
Researchers developed a powder based on morin, extracted from plants like guava leaves, apple peels, and figs, to combat periodontal disease. The study found that the substance can be slowly released through polymers, providing an alternative to antibiotics for controlling microorganisms.
A new review from the University of Victoria suggests that psilocybin and 5-MeO-DMT may help treat concussions and traumatic brain injuries by increasing neuroplasticity and reducing inflammation. The compounds have shown promise in treating depression, anxiety, and other conditions in clinical research.
Researchers have reimagined hemoglobin as an antioxidant protein in the brain, where it breaks down harmful reactive oxygen species. A new compound, KDS12025, selectively enhances this natural defense mechanism to protect against ALS, Parkinson's, Alzheimer's, and autoimmune disorders.
Fucoxanthin reduces oxidative stress, stimulates procollagen production, and inhibits matrix metalloproteinases, suggesting its potential to prevent skin aging and improve skin structure. Animal studies confirm its protective effects against UV-induced damage and wrinkle formation.
A new book by Professor Aldrin Gomes details the benefits and risks of ibuprofen, including its interaction with over 400 prescription drugs and impact on cardiovascular health. The comprehensive guide aims to educate readers about responsible painkiller use and natural alternatives.
Research reveals individuals taking oral steroids for over 3 months are 6 times more likely to be diagnosed with adrenal insufficiency than those treated with non-steroidal anti-inflammatory drugs. Long-term users of inhaled steroids also face increased risk without hospitalisations.
A new approach, GlycoCaging, delivers medicine directly to the lower gut at significantly lower doses than current treatments, potentially helping people with inflammatory bowel disease. The technique has been shown to be effective in mice and has potential for treatment in humans, as most people have the ability to activate the drugs.
Researchers at McGill University have identified a potential new treatment for chronic low back pain by targeting 'zombie cells' in the spine. Two drugs, o-Vanillin and RG-7112, were found to clear zombie cells, reduce pain and inflammation, and slow or reverse damage to spinal discs after eight weeks of treatment.
Researchers have identified six promising biomarkers that can detect drug-induced kidney injury earlier than traditional markers, enabling more timely monitoring during drug development. These biomarkers could lead to the development of safer medications and improve patient outcomes.
Researchers found that ibuprofen inhibits the activation of the sweet taste receptor in people and human cells, affecting glucose metabolism. The study suggests this mechanism could contribute to reduced risk of metabolic diseases such as Alzheimer's, diabetes, and colon cancer.
Researchers found that lower doses (20mg) and higher doses (100mg) of doxycycline were equally effective in treating lymphocytic scarring alopecia, a rare skin condition causing permanent hair loss. The low-dose regimen resulted in fewer side effects and no compromise on efficacy or anti-inflammatory benefit.
A large prospective study found that long-term use of non-steroidal anti-inflammatory (NSAID) medications may help prevent dementia due to their anti-inflammatory effects. The study showed a 12% reduced risk of developing dementia among participants who used NSAIDs for an extended period.
Researchers developed a new method to search through billions of molecules to identify potential anti-inflammatory drug candidates. The method uses computer algorithms to explore vast chemical space and has the potential to speed up the costly drug development process.
A study from the University of Gothenburg found that testosterone increases damage following a heart attack by increasing white blood cell release from bone marrow. This affects both men and women, but has a greater impact on male hearts.
Researchers found associations between antibiotics, antivirals, vaccines, and anti-inflammatory drugs with reduced dementia risk. The study pooled data from over 130 million individuals, identifying potential repurposed treatments for dementia.
The study developed floating nanoballoons to improve ibuprofen's bioavailability and sustained release its anti-inflammatory effects. The formulation showed superior edema inhibition in acute inflammation studies, reducing TNF-α, hs-CRP, and IL-6 levels, while increasing anti-inflammatory IL-10 levels.
A cross-sectional study found that maternal use of certain antidepressants and anti-inflammatory medications can lower protein and fat levels in breast milk. This may impose health risks on infants who are breastfed by mothers taking these medications, highlighting the need for further research to clarify the clinical implications.
Researchers found that methanolic extract and palmatine from Annona squamosa leaves exhibit analgesic, anti-inflammatory, and anti-hyperalgesic properties. Palmatine may be responsible for the plant's anti-arthritic effects. Further studies are needed to confirm these findings and assess their therapeutic potential.
A survey study estimates that 15.6 million US adults consume at least one potentially hepatotoxic botanical product within the past 30 days. Turmeric is the most commonly reported botanical, followed by green tea, ashwagandha, Garcinia cambogia, red yeast rice, and black cohosh products.
Researchers at UVA discovered an unknown cause of long COVID inside lung tissues, promoting chronic inflammation that drives lasting respiratory symptoms. They found that immune cells can go haywire and promote tissue scarring, leading to conditions like interstitial lung disease.
A subset of patients with stage 3 colon cancer who have PIK3CA mutations may benefit from celecoxib treatment, which improved overall survival and reduced disease-free survival rates. The study's findings suggest a potential personalized approach to additional therapy for patients with early-stage colon cancer.
Researchers at University of Cambridge uncover unified healer army of regulatory T cells that constantly move and repair damaged tissue. This discovery has implications for treating various diseases, including autoimmune disorders and infectious diseases.
Researchers at UC Davis Health discovered that mesalamine can replace good bacteria's work in fighting Candida albicans in the gut. The study found that mesalamine maintains a low oxygen environment that prevents fungal growth, reducing the risk of invasive candidiasis.
The Alzheimer's disease treatment landscape is experiencing a significant shift, with numerous potential drugs making their way through clinical trials. Biomarkers have also emerged as a key area of focus, providing valuable information on the drug's impact and allowing for more precise guidance in future trials.
Researchers from Florida Atlantic University suggest that selecting an OTC medication for mild COVID-19 symptoms should be based on the entire benefit-to-risk profile of the patient. They caution against using traditional NSAIDs like ibuprofen and naproxen due to their similar but greater side effect profiles compared to aspirin.
Researchers develop nanovector nanogels that selectively target glial cells involved in spinal cord injury inflammation, reducing damage and improving recovery. The treatment demonstrates potential for modulating glial cells in neurodegenerative diseases like Alzheimer's.
The American Dental Association has released a new clinical practice guideline recommending the use of nonsteroidal anti-inflammatory drugs (NSAIDs) alone or with acetaminophen to manage short-term dental pain in adolescents and adults. The guideline also provides recommendations for prescribing opioid medications, emphasizing caution ...
Women who use non-steroidal anti-inflammatory painkillers alongside hormonal contraception may be at a small increased risk of developing venous thromboembolism. High-risk hormonal contraception and NSAIDs like diclofenac are linked to higher blood clot risks.
Researchers have deciphered a biochemical mechanism explaining how cortisone preparations mediate inflammation-resolving effects in human immune cells. Cortisone influences enzymes involved in the formation of inflammation-resolving messenger substances, inducing resolvins early but impairing function later.
Researchers at Sahmyook University repurposed meclofenamate to treat abnormal respiratory mucus, reducing mucin secretion and characteristics of respiratory mucus. This study offers an alternative solution for patients with respiratory diseases, saving time and costs compared to conventional drug development strategies.
Researchers at Children's Hospital of Philadelphia found that NSAIDs exacerbate C. difficile infections by disrupting epithelial cell mitochondria, sensiting them to toxins. The study shows that NSAIDs and C. difficile toxins work synergistically to increase virulence, leading to increased disease severity and mortality.
Researchers developed nanoparticles that mimic the glycocalyx pattern to treat inflammatory bowel disease. The treatment reduced symptoms and inflammation in mice with IBD, with specific versions showing significant improvement.
A recent University of Kentucky study found that inhibiting the p38 protein in microglia may alter interactions between brain immune cells and Alzheimer's pathology. The research suggests that early inhibition of p38 may be beneficial without causing noticeable adverse effects.
A study found that anti-inflammatory drugs like abatacept and infliximab reduced mortality in severely ill COVID-19 patients when used with standard care. However, these medications did not affect recovery time. The findings suggest that multiple treatment options are available for severe cases of COVID-19.
Researchers have found that honokiol, a compound from magnolia tree bark, inhibits SARS-CoV-2 replication in several cell types, reducing infectious particle production. The compound also shows broad-spectrum activity against other highly pathogenic coronaviruses.
Researchers created organoids from patient tissues to test chemotherapy drugs and identified genetic signatures that predict treatment response, offering high accuracy in personalized drug screening. This breakthrough may help select effective drugs for individual patients, reducing trial and error.
Research finds diclofenac's high variability in metabolism due to UGT2B17, a little-studied enzyme. The study suggests genetic testing and dose adjustments for specific populations can help minimize side effects.